DBV Technologies | DBVT - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amarin USD 143.56M 12.5M 2026-06
BioCryst Pharmaceuticals USD 154.97M 16.62M 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
DBV Technologies USD 174.9M 54.3M 2026-06
Galectin Therapeutics USD 25.6M 2.04M 2024-06
Halozyme Therapeutics USD 163.14M 146.61M 2026-06
Incyte USD 3.98B 33.45M 2026-06
Insmed USD 544.76M 37.42M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
United Therapeutics USD 1.8B 523.5M 2026-06